Shares of VivoSim Labs (VIVS) are rocketing higher on Wednesday after the company announced a $5 million milestone payment from Eli Lilly (LLY) and issued revenue guidance that would make any growth investor's eyes pop.
The stock jumped 18.36% to $0.98 as of publication, even as the broader market showed only modest gains (S&P 500 futures up 0.3%). The move comes after VivoSim disclosed that the first patient had been dosed in a Phase 2 trial for a former inflammatory bowel disease drug program—now owned and developed by Lilly—triggering the milestone payment.
But the real headline-grabber is the fiscal 2027 revenue guidance: VivoSim expects revenue to grow by more than 500%. The company says this will be fueled by strong customer interest in its next-generation 3D human cellular models, which are used for preclinical safety testing. As the FDA pushes for more human-relevant testing models, VivoSim's technology is looking increasingly attractive to pharmaceutical and biotech companies.
And the Lilly payment is just the beginning. VivoSim remains eligible for up to $45 million in additional milestone payments tied to future regulatory and commercial milestones for the drug program. That's a nice potential upside for a company with a current market cap of roughly $50 million.
For context, VivoSim Labs—formerly known as Organovo Holdings Inc.—is a biotechnology company focused on developing FXR314 for inflammatory bowel diseases like ulcerative colitis. It uses 3D human tissues to provide predictive screening and research services to drug developers. The recent milestone payment and revenue forecast highlight VivoSim's growing relevance in the biotech sector, especially as demand for innovative drug testing methodologies increases.
Despite today's surge, the stock still trades near its 52-week low of $0.78, so there's a long way to go before shareholders are fully celebrating. But with a potential $45 million in additional milestones and a 500% revenue growth forecast, VivoSim is giving investors plenty to think about.
